Published
10/30/2024, 10:05The first import-substituting production of sterile medicines - a plant for infusion solutions and ampoule injections that meets international GMP (Good Manufacturing Practice) standards - has started operating in Kyrgyzstan. The project was implemented with the financial support of the Russian-Kyrgyz Development Fund (RKDF), which invested $7.7 million in the plant construction.
The plant's capacity is 18 million vials and 5.7 million ampoule packs per year, which will fully meet the needs of the country's healthcare system for infusion solutions, injectables and eye drops. Artem Novikov, Chairman of the RCFD, noted that the opening of the enterprise is an important step for the domestic pharmaceuticals development. The Fund not only financed the project but also provided technical support at the design stage, which allowed to сonstruct the plant which meet high international quality standards.
The plant is an automated production facility for sterile drugs, which controls the quality of products at every stage, from pharmaceutical polyethene to packaging. The project was also a breakthrough in terms of financing: for the first time, RKDF allocated funds for the development of a feasibility study and detailed design of the plant for $90 thousand.
